LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Prothena Corp PLC

Chiusa

SettoreSettore sanitario

5.39 6.52

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

5.01

Massimo

5.43

Metriche Chiave

By Trading Economics

Entrata

-2.2M

-60M

Vendite

705K

2.8M

EPS

-1.12

Margine di Profitto

-2,128.536

Dipendenti

163

EBITDA

-682K

-65M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+380.04% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-495M

251M

Apertura precedente

-1.13

Chiusura precedente

5.39

Notizie sul Sentiment di mercato

By Acuity

50%

50%

167 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Prothena Corp PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 giu 2025, 20:45 UTC

Utili

Broadcom 2Q Sales Climb on Booming AI Demand

5 giu 2025, 23:45 UTC

Discorsi di Mercato

Nikkei May Decline as Caution Over U.S. Economy Continues -- Market Talk

5 giu 2025, 23:44 UTC

Discorsi di Mercato

Gold Edges Higher on Weak U.S. Data -- Market Talk

5 giu 2025, 23:30 UTC

Discorsi di Mercato

NZME Cost Cuts Can Cushion Effect of Weak Market -- Market Talk

5 giu 2025, 21:32 UTC

Utili

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 giu 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

5 giu 2025, 20:45 UTC

Utili

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 giu 2025, 20:24 UTC

Utili

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 giu 2025, 20:15 UTC

Utili

Broadcom 2Q Cont Ops EPS $1.03 >AVGO

5 giu 2025, 20:15 UTC

Utili

Broadcom 2Q Rev $15B >AVGO

5 giu 2025, 20:15 UTC

Utili

Broadcom 2Q Net $4.97B >AVGO

5 giu 2025, 20:15 UTC

Utili

Broadcom 2Q Adj EPS $1.58 >AVGO

5 giu 2025, 20:15 UTC

Utili

Broadcom 2Q EPS $1.03 >AVGO

5 giu 2025, 20:15 UTC

Utili

Broadcom Sees 3Q Rev $15.8B >AVGO

5 giu 2025, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

Constellation Energy: Transaction Is Expected to Close in the 4Q >CEG

5 giu 2025, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

Constellation Energy: Calpine Deal Clears Texas Regulatory Review

5 giu 2025, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

Constellation Energy: With Approval From PUCT Secured, Transaction Awaits Clearance From NY State Public Service Commission, Federal Energy Regulatory Commission and DOJ >CEG

5 giu 2025, 19:22 UTC

Discorsi di Mercato

Oil Futures Resume Upward Moves -- Market Talk

5 giu 2025, 19:00 UTC

Discorsi di Mercato

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

5 giu 2025, 18:32 UTC

Discorsi di Mercato

Gold Slips After Trump-Xi Call -- Market Talk

5 giu 2025, 18:26 UTC

Utili

These Stocks Are Moving the Most Today: Broadcom, Tesla, Circle, Brown-Forman, MongoDB, Planet Labs, ChargePoint, Ciena, and More -- Barrons.com

5 giu 2025, 18:06 UTC

Discorsi di Mercato

Transpacific Ship Freight Rates Spike on China Tariff Truce -- Market Talk

5 giu 2025, 16:30 UTC

Acquisizioni, Fusioni, Takeovers

Vallourec Completes The Acquisition Of Thermotite Do Brasil >VK.FR

5 giu 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

5 giu 2025, 16:18 UTC

Discorsi di Mercato

U.S. Natural Gas Market Shrugs Off Big Storage Build -- Market Talk

5 giu 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

5 giu 2025, 16:12 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

5 giu 2025, 16:12 UTC

Discorsi di Mercato

Copper Prices Rise on Positive Signals From Trump on China Trade Talks -- Market Talk

5 giu 2025, 16:03 UTC

Discorsi di Mercato

U.S. Diesel, Gasoline Futures Pick Back Up -- Market Talk

5 giu 2025, 15:49 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Prothena Corp PLC Previsione

Obiettivo di Prezzo

By TipRanks

380.04% in crescita

Previsioni per 12 mesi

Media 24.29 USD  380.04%

Alto 81 USD

Basso 4 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Prothena Corp PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

9 ratings

4

Acquista

4

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

N/A / 7.35Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Very Strong Bearish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

167 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.